ImmunityBio, Inc. (IBRX)
IBRX Stock Outlook After Q1 Results and a New FDA Review
ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.
ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout
ImmunityBio is transitioning into a scalable bladder cancer immunotherapy platform, driven by accelerating Anktiva adoption and robust revenue growth. 1Q26 revenue surged 168% YoY to $44.2M, with strong physician uptake, but operating expenses and adjusted net loss ($86.2M) remain elevated amid heavy investment. The papillary sBLA for Anktiva is a key near-term catalyst; regulatory uncertainty persists, but compelling QUILT-3.032 data and prior FDA approval in CIS support optimism.
FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer Therapy
ImmunityBio's shares rise after the FDA accepts a filing to expand Anktiva's use in bladder cancer, with a decision due by January 2027.
ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder Cancer
IBRX secures five U.S. patents for Anktiva in bladder cancer, extending franchise protection through 2035 amid strong sales growth.
ImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAM
ImmunityBio, Inc. receives a Strong Buy rating, driven by ANKTIVA's compelling clinical data and major regulatory catalysts ahead. ANKTIVA's unique IL-15 mechanism boosts lymphocyte proliferation, showing strong efficacy in solid cancers with lymphopenia and outperforming prior immunotherapies. QUILT trial results validate lymphocyte count as a survival biomarker, supporting likely BLA approval and unlocking broad oncology opportunities.
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.15 per share a year ago.
IBRX Global Rollout: EU, MENA, and Asia Shape 2026-27 Catalysts
ImmunityBio's global push spans EU, MENA, and Asia, with early Saudi sales and key 2026 data readouts set to test demand and drive next growth phase.
IBRX: What Anktiva's Bladder Data Says About 2026 Sales
ImmunityBio heads into 2026 riding Anktiva growth, but upcoming bladder trial data and broader use in earlier care will be key to sustaining momentum.
Is IBRX Priced for Perfection at Nearly 28x Forward Sales?
ImmunityBio IBRX has delivered a stunning rerating in 2026. After a move like this, investors often stop debating the story and start debating the price.
What Makes ImmunityBio (IBRX) a New Buy Stock
ImmunityBio (IBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Reframing ImmunityBio: The Long-Term Platform Opportunity Beyond Anktiva
ImmunityBio is transitioning from a single-product biotech to a potential multi-billion-dollar oncology and cell therapy platform company. Anktiva's commercial momentum is strong, with 1Q26 revenue up 168% YoY and FY25 revenue reaching $113 million, supported by guideline inclusion and global approvals. The Leonardo platform is central to the long-term bull case, aiming to industrialize NK-cell therapies through scalable manufacturing and hospital partnerships.
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results
ImmunityBio stock jumps 7% as Q1 2026 revenues surge 168% on strong Anktiva uptake, with expanding approvals and pipeline progress boosting momentum.
